Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating CD19-targeted CAR T cells for relapsed/refractory mantle cell lymphoma is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CD19-targeted CAR T cells

Snippet

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd. | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING